BP
Gilead Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Yescarta (axicabtagene ciloleucel) | Relapsed/Refractory Large B-Cell Lymphoma | Approved |
| Tecartus (brexucabtagene autoleucel) | Relapsed/Refractory Mantle Cell Lymphoma | Approved |
| Bictegravir/TAF/FTC (Biktarvy) | HIV-1 Infection | Approved |
| Sofosbuvir/Velpatasvir (Epclusa) | Chronic Hepatitis C | Approved |
| Remdesivir (Veklury) | COVID-19 | Approved |
| Lenacapavir | HIV Prevention | Phase 3 |
| Magrolimab | Myelodysplastic Syndrome | Phase 3 |
| Filgotinib | Ulcerative Colitis | Phase 3 |
Leadership Team at Gilead Sciences
DO
Daniel O'Day
Chairman and Chief Executive Officer
JM
Johanna Mercier
Chief Commercial Officer
AD
Andrew Dickinson
Chief Financial Officer
MP
Merdad Parsey
Chief Medical Officer
FM
Flavius Martin
Chief Scientific Officer
JF
Jacqualyn Fouse
Chief Executive Officer, Kite
KY
Kevin Young
Chief Operating Officer